Ex-Teva chief resurfaces at biotech startup; Merck extends Ablynx deal;

@FierceBiotech: $AMGN uncovers trove of gene knockouts in 'molecular national selfie.' Story | Follow @FierceBiotech

@JohnCFierce: ICYMI: Not giving up day job, but interviewing @Asthika from Bloomberg Intelligence on biotech market was fun. Watch | Follow @JohnCFierce

@DamianFierce: Sivextro v. Sovaldi. Vimizim v. Movantik. Belsomra lost?!? It's the Sweet 16 in @FiercePharma's #FierceMadness. Vote | Follow @DamianFierce

> Former Teva ($TEVA) CEO Jeremy Levin is back in biopharma, serving as chairman of upstart Ovid Therapeutics as the company pursues treatments for rare neurological diseases. More

> U.K. biotech Redx Pharma executed a £15 million ($22 million) IPO on the London exchange. Item

> Merck ($MRK) has extended its antibody R&D deal with Ablynx. Release

> The U.K.'s Biomedical Catalyst Fund is setting out another £40 million ($59 million) to support biotech projects around the country. News

Medical Device News

@FierceMedDev: ICYMI yesterday: Novartis rides med tech wave with new digital projects. Article | Follow @FierceMedDev

@EmilyWFierce: Cipla revs up for generic Sovaldi launch in India. FiercePharma story | Follow @EmilyWFierce

> J&J's DePuy inks deal with Radlink to market imaging tech with hip replacement devices. Article

> Zimmer: New outpatient program for Persona Knee patients is succeeding. Report

Pharma News

@FiercePharma: Germany's cost watchdog decides Valeant's Provenge has added benefit after all. FierceVaccines story | Follow @FiercePharma

@EricPFierce: IPCA says FDA bans will have little sales impact. Didn't Wockhardt make that claim before its profits sank? Story | Follow @EricPFierce

@CarlyHFierce: Legal fallout from Valeant's failed Allergan siege? Experts debate. Story | Follow @CarlyHFierce

> J&J CEO Gorsky sees 'new horizon' in China, despite slowing growth. More

> What does Merck's $10B buyback plan say about pharma M&A? Article

CRO News

> Recipharm pairs up with Adroit for chemistry services. Item

> Ergomed reaches into Asia on the hunt for co-development deals. Article

> BioClinica expands in NC after a string of buyouts. More

> Icon taps Carnegie Mellon to help patients better understand trials. Story

Vaccines News

> GlaxoSmithKline takes TB vaccine to Phase IIb. Item

> Emergent BioSolutions nabs government funds to test new-and-improved anthrax vaccine. News

> Chinese Ebola vaccine based on current strain looks safe in PhI. Story

> Germany's cost watchdog decides Valeant's Provenge has added benefit after all. Report

> GSK, U.K. 'hopeful' they can strike a Bexsero price deal soon. Article

Pharma Manufacturing News

> Indian state to train employees to think like FDA inspectors. Item

> San Francisco requires drugmakers to fund disposal of unused meds. News

> Tolmar adds warehouse to support new manufacturing facility. Article

> Deal done, Sun Pharma must now fix Ranbaxy's deep problems. Story

> FDA bans 2 more IPCA plants. More

Pharma Asia News

> U.S.-based Chinese researcher pleads guilty in United Imaging Healthcare bribery case. Report

> Pleasantries aside, U.S. FDA keeps sharp eye on India pharma manufacturing. Article

> Glenmark on yo-yo string sales journey with diabetes generics in U.S. More

> Actelion's PAH drug Opsumit gets Japan marketing nod, GSK's Encruse approved. Story

> Japan's MHLW approves Gilead's Sovaldi for genotype 2 chronic hep C. Article

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.